Ganetespib and HSP90: translating preclinical hypotheses into clinical promise
- PMID: 24556722
- DOI: 10.1158/0008-5472.CAN-13-3263
Ganetespib and HSP90: translating preclinical hypotheses into clinical promise
Abstract
As with many physiologic processes that become subverted during tumorigenesis, the chaperoning activity of heat shock protein 90 (HSP90) is often exploited by cancer cells to confer aberrant proliferative, survival, and/or metastatic potential. Functional inhibition of HSP90 results in the degradation of its client proteins, in turn providing a means to concomitantly disrupt multiple oncogenic signaling cascades through one molecular target. Pharmacologic blockade of HSP90 has, therefore, emerged as an innovative and multifaceted approach for the development of new antineoplastic agents. However, no HSP90 inhibitors are currently approved for cancer therapy and the full promise of this class of agents is yet to be realized. This review focuses on the preclinical activity profile of ganetespib, a potent small-molecule inhibitor of HSP90, the characterization of which has provided important frameworks for the optimal design and application of HSP90 inhibitor-based strategies in a variety of cancer types. Beyond client protein-driven tumors, ganetespib can also potentiate the effects of other molecularly targeted and standard-of-care therapeutics while simultaneously overcoming drug resistance in multiple tumor types, thereby positioning this compound as the leading HSP90 inhibitor currently under clinical development.
©2014 AACR
Similar articles
-
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.Clin Cancer Res. 2014 Jan 15;20(2):413-24. doi: 10.1158/1078-0432.CCR-13-2166. Epub 2013 Oct 30. Clin Cancer Res. 2014. PMID: 24173541
-
Recent updates on the development of ganetespib as a Hsp90 inhibitor.Arch Pharm Res. 2012 Nov;35(11):1855-9. doi: 10.1007/s12272-012-1101-z. Arch Pharm Res. 2012. PMID: 23212626 Review.
-
HSP90 inhibitors for cancer therapy and overcoming drug resistance.Adv Pharmacol. 2012;65:471-517. doi: 10.1016/B978-0-12-397927-8.00015-4. Adv Pharmacol. 2012. PMID: 22959035 Review.
-
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5. Mol Cancer Ther. 2012. PMID: 22144665
-
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.Curr Opin Investig Drugs. 2010 Dec;11(12):1466-76. Curr Opin Investig Drugs. 2010. PMID: 21154128 Review.
Cited by
-
Mechanism of Musashi2 affecting radiosensitivity of lung cancer by modulating DNA damage repair.MedComm (2020). 2024 Apr 21;5(5):e548. doi: 10.1002/mco2.548. eCollection 2024 May. MedComm (2020). 2024. PMID: 38645664 Free PMC article.
-
Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress.Arch Pharm Res. 2024 May;47(5):442-464. doi: 10.1007/s12272-024-01494-1. Epub 2024 Apr 17. Arch Pharm Res. 2024. PMID: 38632167 Review.
-
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.Cancer Commun (Lond). 2024 Mar;44(3):297-360. doi: 10.1002/cac2.12520. Epub 2024 Feb 4. Cancer Commun (Lond). 2024. PMID: 38311377 Free PMC article. Review.
-
Nanoreceptors promote mutant p53 protein degradation by mimicking selective autophagy receptors.Nat Nanotechnol. 2024 Apr;19(4):545-553. doi: 10.1038/s41565-023-01562-5. Epub 2024 Jan 12. Nat Nanotechnol. 2024. PMID: 38216684
-
Combination therapy with HSP90 inhibitors and piperlongumine promotes ROS-mediated ER stress in colon cancer cells.Cell Death Discov. 2023 Oct 13;9(1):375. doi: 10.1038/s41420-023-01672-y. Cell Death Discov. 2023. PMID: 37833257 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials